Literature DB >> 20347397

Issues in second trimester induced abortion (medical/surgical methods).

Vivian C Y Lee1, Ernest H Y Ng, P C Ho.   

Abstract

Second trimester abortion remains a common procedure worldwide. Dilatation and evacuation (D&E) is the surgical method of choice, if the surgical expertise and facilities are available. Adequate cervical dilatation preoperatively is a prerequisite for a safe D&E. Medical abortion using misoprostol together with mifepristone is the medical method of choice. The recommended regimen is 200mg mifepristone followed by 800 microg of vaginal misoprostol 36-48 h later. Subsequent doses of 400 microg of misoprostol can be given orally every 3h up to a maximum of four more doses. Proper preoperative assessment would not only help to provide safe abortion treatment, but it also guides the choice of method. If the expertise and facilities of both methods are available, both methods should be discussed and offered to the patient so that the patient can make an informed choice. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20347397     DOI: 10.1016/j.bpobgyn.2010.02.008

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  3 in total

1.  Uterine artery embolization for hemorrhage resulting from second-trimester abortion in women with scarred uterus: report of two cases.

Authors:  Yunfeng Shen; Yumei Liao; Guangsen Feng; Xiaoli Gu; Shi Wan
Journal:  Int J Clin Exp Med       Date:  2015-08-15

2.  Biological, Behavioral and Physiological Consequences of Drug-Induced Pregnancy Termination at First-Trimester Human Equivalent in an Animal Model.

Authors:  Christina Camilleri; Rebecca M Beiter; Lisett Puentes; Paula Aracena-Sherck; Stephen Sammut
Journal:  Front Neurosci       Date:  2019-05-29       Impact factor: 4.677

3.  Efficacy of second-trimester termination procedure; medical, mechanic, or combine?

Authors:  Tuncay Yüce; Dilek Yüksel; Erkan Kalafat; Acar Koç
Journal:  Interv Med Appl Sci       Date:  2018-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.